Alain Le Moine

Alain Le Moine

orcid

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
10 February 2023 in American Journal of Transplantation
Verified
Journal Article
Open access
DKDelphine Kemlin
Delphine Kemlin
NGNicolas Gemander
Nicolas Gemander
SDStéphanie Depickère
Stéphanie Depickère
VOVéronique Olislagers
Véronique Olislagers
DGDaphnée Georges
Daphnée Georges
AMArnaud Marchant
Arnaud Marchant
As solid organ transplant recipients are at high risk of severe COVID-19 and respond poorly to primary SARS-CoV-2 mRNA vaccination, they have been prioritized for booster vaccination. However, an immunological correlate of protection has not been identified in this vulnerable population. We conducted a prospective monocentric cohort study of 65 kidney transplant recipients who received 3 doses of BNT162b2 mRNA vaccine. Associations among breakthrough infection (BTI), vaccine responses, and patient characteristics were explored in 54 patients. Symptomatic COVID-19 was diagnosed in 32% of kidney transplant recipients during a period of 6 months after booster vaccination. During this period, SARS-CoV-2 delta and omicron were the dominant variants in the general population. Univariate Analyses identified the avidity of SARS-CoV-2 receptor binding domain binding IgG, neutralizing antibodies, and SARS-CoV-2 S2-specific interferon gamma responses as correlates of protection against BTI. No demographic or clinical parameter correlated with the risk of BTI. In multivariate analysis, the risk of BTI was best predicted by neutralizing antibody and S2-specific interferon gamma responses. In conclusion, T cell responses may help compensate for the suboptimal antibody response to booster vaccination in kidney transplant recipients. Further studies are needed to confirm these findings.

30 December 2022 in American Journal of Transplantation
Verified
Journal Article
Open access
DKDelphine Kemlin
Delphine Kemlin
ALAnne Lemy
Anne Lemy
PPPieter Pannus
Pieter Pannus
IDIsabelle Desombere
Isabelle Desombere
NGNicolas Gemander
Nicolas Gemander
AMAlain Le Moine
Alain Le Moine

10 December 2021 in Frontiers in Medicine
Verified
Journal Article
Open access
GGGiuseppe Gambino
Giuseppe Gambino
CCConcetta Catalano
Concetta Catalano
MMMartina Marangoni
Martina Marangoni
CGCaroline Geers
Caroline Geers
AMAlain Le Moine
Alain Le Moine
LGLidia Ghisdal
Lidia Ghisdal
Background: Ciliopathies are rare diseases causing renal and extrarenal manifestations. Here, we report the case of a ciliopathy induced by a homozygous pathogenic variant in the TTC21B gene.Case Description: A 47-year-old patient started hemodialysis for chronic kidney disease (CKD) of unknown origin. She presented with early onset of hypertension, pre-eclampsia, myopia and cirrhosis. Renal biopsy showed mild interstitial fibrosis, tubular atrophy, and moderate arteriosclerosis while liver pathology demonstrates grade B biliary cirrhosis. Family history revealed several cases of early-onset severe hypertension and one case of end-stage renal disease (ESRD) needing kidney transplantation at twenty years of age. Clinical exome sequencing showed homozygosis for the pathogenic variant c.626C>T (p.Pro209Leu) in the TTC21B gene. The patient underwent combined liver-renal transplantation with an excellent renal and hepatic graft outcome.Conclusions:TTC21B gene mutations can lead heterogeneous to clinical manifestations and represent an underappreciated cause of ESRD. The paradigm in diagnosis of CKD of early onset and/or of unknown origin is changing and genetic counseling should be performed in all patients and families that meet those criteria. Renal or combined liver-renal transplantation represents the best option for patients suffering from those diseases in terms of prognosis and quality of life.

15 May 2024 in Biomedicines
Verified
Journal Article
Open access
PDF file
BCBenedetta Chiodini
Benedetta Chiodini
PGPauline Guillaume-Gentil
Pauline Guillaume-Gentil
CVCharlotte Vanhomwegen
Charlotte Vanhomwegen
EHELISE HENNAUT
ELISE HENNAUT
KLKsenija Lolin
Ksenija Lolin
KIKhalid Ismaïli
Khalid Ismaïli
BK polyomavirus (BKPyV) is still a real threat in the management of kidney transplantation. Immunosuppressive treatment disrupts the equilibrium between virus replication and immune response, and uncontrolled BKPyV replication leads to nephropathy (BKPyV nephropathy). The first evidence of BKPyV reactivation in transplant recipients is the detection of viral shedding in urine, which appears in 20% to 60% of patients, followed by BKPyV viremia in 10–20% of kidney transplant recipients. BKPyV nephropathy eventually occurs in 1–10% of this population, mainly within the first 2 years post-transplantation, causing graft loss in about half of those patients. Few data exist regarding the pediatric population and we focus on them. In this paper, we review the existing diagnostic methods and summarize the evidence on the role of BKPyV humoral and cellular immunity in modulating the clinical course of BKPyV infection and as potential predictors of the outcome. We look at the known risk factors for BKPyV nephropathy in the immunosuppressed patient. Finally, we propose a sensible clinical attitude in order to screen and manage BKPyV infection in kidney transplant children.

30 January 2025 in Human Immunology
Verified
Journal Article
Closed access
MCMargaret C. Carpenter
Margaret C. Carpenter
SSSweta Shrestha
Sweta Shrestha
PBPranay Bharadwaj
Pranay Bharadwaj
CCCatalano Concetta
Catalano Concetta
SSShilpee Sharma
Shilpee Sharma
MAMargaret E Ackerman
Margaret E Ackerman

8 April 2024 in Preprints.org
Verified
Preprint
Open access
PDF file
BCBenedetta Chiodini
Benedetta Chiodini
GPGuillaume-Gentil Pauline
Guillaume-Gentil Pauline
CVCharlotte Vanhomwegen
Charlotte Vanhomwegen
EHELISE HENNAUT
ELISE HENNAUT
KLKsenija Lolin
Ksenija Lolin
KIKhalid Ismaïli
Khalid Ismaïli
BK polyomavirus (BKPyV) is still a real threat in the management of kidney transplantation. Immunosuppressive treatment disrupts the equilibrium between virus replication and immune response, and uncontrolled BKPyV replication leads to nephropathy (BKPyV nephropathy). The first evidence of BKPyV reactivation in transplant recipients is the detection of viral shedding in urine, which appears in 20% to 60% of patients, followed by BKPyV viremia in 10-20% of kidney transplant recipients. BKPyV nephropathy eventually occurs in 1-10% of this population, mainly within the first 2 years post-transplantation, causing graft loss in about half of those patients. Few data exist regarding the pediatric population and we focus on them. In this paper, we review the existing diagnostic methods, we summarize the evidences on the role of BKPyV humoral and cellular immunity in the modulation of the clinical course of BKPyV infection and as potential predictors of the outcome. We look at the known risk factors of BKPyV nephropathy in the immunosuppressed patient. Finally, we propose a sensible clinical attitude in order to screen and manage BKPyV infection in kidney transplant children.